Clinical oral doses of dexamethasone decreases intrinsic clearance of quinidine, a cytochrome P450 3A substrate in dogs

Journal of Veterinary Medical Science

Volumn 68, Issue 9, 2006, Pages 903-907

  Zhang, Kewei ^a   Kohno, Sayaka ^a   Kuroha, Masanori ^a   Kokue, Eiichi ^a   Shimoda, Minoru ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Canine; Clearance; CYP3A; Dexamethasone; Quinidine

Indexed keywords

CYTOCHROME P450 3A; DEXAMETHASONE; QUINIDINE;

ANIMAL; ARTICLE; BLOOD; CLINICAL TRIAL; DOG; DRUG INTERACTION; MALE; METABOLISM;

ANIMALS; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DOGS; DRUG INTERACTIONS; MALE; QUINIDINE;

CANIS FAMILIARIS;

EID: 33749505832     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.68.903     Document Type: Article

References (21)

1. Abramson, F.P. 1988. Dose-response behavior of the induction of alpha 1-acid glycoprotein by phenobarbital in the dog. Drug. Metab. Dispos. 16: 546-550.
2. Clohisy, D.R. and Gibson, T.P. 1982. Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. J. Cardiovasc. Pharmacol. 4: 107-110.
3. Corpier, C.L., Jones, P.H., Suki, W.N., Lederer, E.D., Quinones, M.A. Schmidt, S.W. and Young, J.B. 1988. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 260: 239-241.
4. Donald, C.P. 1999. pp. 178-180. In: Veterinary Drug Handbook, 3rd ed. (Donald C.P., ed.) Iowa State University Press.
5. Doumas, B. T., Watson, W. A. and Biggs, H. G. 1971. Albumin standards and the measurement of serum albumin with bromcresol green. Clinica Chimica Acta 31: 87-96.
6. Dresser, G.K., Spence, J.D. and Bailey, D.G. 2000. Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38: 41-57.
7. Eeckhoudt, S.L., Horsmans, Y. and Verbeeck, R.K. 2002. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32: 975-984.
8. Ikenoue, N., Saitsu, Y., Shimoda, M. and Kokue, E. 2000. Disease-induced alterations in plasma drug-binding proteins and their influence on drug binding percentages in dogs. Vet. Q. 22: 43-49.
9. Itoh, Y., Okanoue, T., Enjo, F., Sakamoto, S., Takami, S., Yasui, K., Kagawa, K. and Kashima, K. 1994. Regulation of hepatocyte albumin and alpha 1-acid glycoprotein secretion by monokines, dexamethasone, and nitric oxide synthase pathway: significance of activated liver nonparenchymal cells. Dig Dis. Sci. 39: 851-860.
10. Kocarek, T.A., Schuetz, E.G., Strom, S.C., Fisher, R.A. and Guzelian, P.S. 1995. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos. 23: 415-421.
11. Kuroha, M., Shirai, Y. and Shimoda, M. 2004. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs. J. Vet. Pharmacol. Ther. 27: 355-359.
12. Kuroha, M., Son, D.S. and Shimoda, M. 2001. Effects of altered plasma alpha-1-acid glycoprotein levels on pharmacokinetics of some basic antibiotics in pigs: simulation. analysis. J. Vet. Pharmacol. Ther. 24: 423-431.
13. Mullins, M.E., Horowitz, B.Z., Linden, D.H., Smith, G.W., Norton, R.L. and Stump, J. 1998. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 280: 157-158.
14. Pichard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G. and Maurel, P. 1990. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug, Metab, Dispos. 18: 595-606.
15. Pohjola-Sintonen, S., Viitasalo, M., Toivonen, L and Neuvonen, P. 1993. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45: 191-193.
16. Pous, C., Giroud, J.P., Damais, C., Raichvarg, D. and Chauvelot-Moachon, L. 1990. Effect of recombinant human interleukin-1 beta and tumor necrosis factor alpha on liver cytochrome P-450 and serum alpha-1-acid glycoprotein concentrations in the rat. Drug. Metab. Dispos. 18: 467-470.
17. Shimada, T., Terada, A., Yokogawa, K., Kaneko, H., Nomura, M., Kaji, K., Kaneko, S., Kobayashi, K. and Miyamoto, K. 2002. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 74: 1419-1424.
18. Shimoishi, K., Kai, H., Kabu, K., Komori, T., Maruyama, T. and Otagiri, M. 2001. FK506 (tacrolimus) increases rat alpha1-acid glycoprotein expression in liver and primary cultured hepatocytes. Eur. J. Pharmacol. 25: 91-95.
19. Watanabe, M., Tateishi, T., Asoh, M., Nakura, H., Tanaka, M., Kumai, T. and Kobayashi, S. 1998. Effect of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. Life Sci. 63: 1685-1692.
20. Yamaoka, K., Tanigawara, Y., Nakagawa, T., and Uno, T. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodynamics 4: 879-885.
21. Zhang, K., Kuroha, M., Shibata, Y., Kokue, E. and Shimoda, M. Clinical oral doses of dexamethasone down-regulate cytochrome P450 3A subfamily in dogs. Am. J. Vet. Res. (submitted).